Inhibition by Argatroban, a Specific Thrombin Inhibitor, of Platelet Activation by Fibrin Clot-associated Thrombin

Summary

Clot-associated thrombin retains amidolytic activity, and is resistant to inhibition by heparin, but not to low molecular weight thrombin inhibitors. We show that clot-associated thrombin induces platelet aggregation, is resistant to heparin:antithrombin III, less so to recombinant hirudin (rHV2Lys47) but not to argatroban, an active-site directed thrombin inhibitor. Fibrin clots prepared with human fibrinogen and thrombin were used to aggregate rabbit washed platelets assessed by single platelet counting, thromboxane B₂ (TXB₂) immunoassay and scanning electron microscopy. Fibrin clots decreased platelet counts, and released TXB₂. Electron microscopy showed platelet aggregates on the clot surface. Argatroban concentration-dependently inhibited such aggregation with IC₅₀s of 21 nM and 13 nM versus aggregation and TXB₂ release respectively. The IC₅₀s of Argatroban against fluid-phase thrombin producing similar aggregation were 12 nM (aggregation) and 33 nM (TXB₂). rHV2Lys47 was less active against clot-induced aggregation (IC₅₀ = 1.8 nM) than against fluid-phase thrombin (IC₅₀ = 0.06 nM). Heparin had an IC₅₀ of 0.02 mU/ml against aggregation induced by fluid-phase thrombin, but much greater concentrations are required to inhibit clot-induced aggregation (IC₅₀ = 48 mU/ml). These data provide a basis for the superiority of direct-acting thrombin inhibitors over heparin in platelet rich thrombi.

• References

• 1 Liu CY, Kaplan KL, Markowitz AH, Nossel HL. The binding of thrombin to fibrin. J Biol Chem 1979; 254: 10421-10425
• 2 Kaminski M, McDonagh J. Studies on the mechanism of thrombin interaction with fibrin. J Biol Chem 1983; 258: 7627-7630
• 3 Kaminski M, McDonagh J. Inhibited thrombins: Interactions with fibrinogen and fibrin. J Biol Chem 1987; 262: 881-887
• 4 Berliner LJ, Sugawara Y, Fenton JWII. Human α-thrombin binding to fibrin-sepharose: Evidence for an anionic binding site. Biochemistry 1985; 24: 7005-7009
• 5 Wilner GD, Danitz MP, Mudd MS, Hsieh KH, Fenton JW II. Selective immobilisation of α-thrombin by surface bound fibrin. J Lab Clin Med 1981; 97: 403-411
• 6 Fenton JW II, Zabinski MP, Hsieh K, Wilner GD. Thrombin noncovalent-protein binding and fibrin(ogen) recognition. Thromb Haemost 1981; 46: 177
• 7 Vali Z, Scheraga H. The localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry 1988; 27: 1956-1963
• 8 Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-t-PA-induced thrombolysis. Blood 1989; 74: 1025-1030
• 9 Haskel EJ, Eisenberg PR, Abendschein DR. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood. Blood Coagulation Fibrinolysis 1993; 4: 07-13
• 10 Naski MC, Shafer JA. α-Thrombin within fibrin clots: Inactivation of thrombin by antithrombin-III. Thromb Res 1993; 69: 453-465
• 11 Weitz JI, Hudoba M, Masel D, Maraganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 1990; 86: 385-391
• 12 Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-386
• 13 Kettner C, Shaw E. D-Phe-Pro-Arg CH₂Cl. A selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
• 14 Naski MC, Fenton JW II, Maraganore JM, Olsen ST, Shafer JA. The COOH-terminal domain of hirudin. J Biol Chem 1990; 265: 13484-13489
• 15 Okamoto S, Hijikata A, Kikumoto R, Tonomara S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereo-struc-ture of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-446
• 16 Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Selective inhibition of thrombin by (2R,4R)-4-Methyl-l-[N²-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-arginyl]-2-piperidinecar-boxylic acid. Biochemistry 1984; 23: 85-90
• 17 Imura Y, Stassen J-M, Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharm Exp Ther 1992; 261: 895-898
• 18 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225
• 19 Fujioka K. The Effect of MD-805 on experimental acute arterial thrombosis in relation to vasoactive prostanoids (TXA₂ and PGI₂). J Jap Coll Angiol 1989; 29: 57-64
• 20 Eidt JF, Allison P, Noble S, Ashton J, Golino P, Mcnatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27
• 21 Berry CN, Girard D, Lochot S. Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-1214
• 22 Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, Mineo K, Okamoto S. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Haemost 1986; 56: 28-34
• 23 Jang I-K, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalisation with recombinant tissue-type plasminogen activator. Circulation Research 1990; 67: 1552-1561
• 24 Schneider J. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis. Thrombosis Res 1991; 64: 677-689
• 25 Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-722
• 26 Fitzgerald DJ, Fitzgerald GA. Role of thrombin and thromboxane A₂ in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci 1989; 86: 7585-7589
• 27 Mellot MJ, Connolly TM, York SJ, Bush LR. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb Haemost 1990; 64: 526-534
• 28 Jen CJ, Lin JS. Direct observation of platelet adhesion to fibrinogen- and fibrin-coated surfaces. Am J Physiol 1991; 261 H 1457-1463
• 29 Hamaguchi M, Bunce LA, Sporn LA, Francis CW. Spreading of platelets on fibrin is mediated by the amino terminus of the β-chain including peptide β15-41. Blood 1993; 9: 2348-2356
• 30 Kumar R, Béguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot-bound thrombin. Thromb Haemost 1994; 72: 713-721
• 31 White GC, Lapetina EG. Agonists and receptors: thrombin. In: Platelet Responses and Metabolism Vol. II Holmsen H. ed CRC Press; Boca Raton, Florida: 1987. pp 03-18
• 32 Berry CN, Lunven C, Lecoffre C, O’Brien D, Gauffeny C, Roome NO. Platelet activation by clot-associated thrombin: inhibition by argatroban, a specific thrombin inhibitor. Br J Pharmacol 1995; 114 (Procs. Suppl.) 122
• 33 Vargas JR, Radomski M, Moncada S. The use of prostacyclin in the separation from plasma and washing of human platelets. Prostaglandins 1982; 23: 929-945
• 34 Gear ARL. In vitro platelet responses: aggregation. In: Platelet Responses and Metabolism Vol. I Holmsen H. ed CRC Press; Boca Raton, Florida: 1987. pp 097-114
• 35 Kinlough-Rathbone RL, Packham MA, Reimers HJ, Cazenave JP, Mustard JF. Mechanisms of platelet shape change, aggregation and release induced by collagen, thrombin or A23,187. J Lab Clin Med 1977; 90: 707-716
• 36 Hara H, Tamao Y, Kikumoto R. Effect of argatroban (MD-805) on platelet function. Jap Pharmacol Ther 1986; 14 (Suppl) (Suppl. 05) 13-19
• 37 Hantgan RR, Endenberg SC, Cavero I, Marguerie G, Uzan A, Sixma JJ, de Groot PG. Inhibition of platelet adhesion to fibrin(ogen) in flowing whole blood by Arg-Gly-Asp and fibrinogen γ-chain carboxy terminal peptides. Thromb Haemost 1992; 68: 694-700
• 38 Rubens FD, Perry DW, Hatton MWC, Bishop PD, Packham MA, Kinlough-Rathbone RL. Platelet accumulation on fibrin-coated polyethylene: role of platelet activation and factor XIII. Thromb Haemost 1995; 73: 850-856
• 39 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-29
• 40 Bevers EM, Comfurius P, Van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phophatidyl-serine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-436
• 41 Tuddenham EGD, Cooper DN. Prothrombin. In: The molecular genetics of haemostasis and its inherited disorders Oxford Medical Press; Oxford: 1994. pp 134-148
• 42 Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemost 1990; 63: 44-47
• 43 Kelly AB, Marzee UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012
• 44 Berry CN, Girard D, Girardot C, Lochot S, Lunven C, Visconte C. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Semin Thromb Haemost 1995 in press